ERBB2 and cancer: Speculatively, hybrid nanoplatforms of drug-carrying radioactive nanoparticles hybridized with ADCs via MnFe2O4 would permit theranostic use, with MRI monitoring the drug release in cancers caused by HER2, where therapy resistance due to reduced drug delivery may be averted by a 40–60% regulated dose.